Wednesday - July 16, 2025
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
7th Annual Evercore HealthCONx Conference
Tuesday, December 3, 2024, at 10:00 a.m. ET
Citi 2024 Global Healthcare Conference
Wednesday, December 4, 2024, at 2:30 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit www.travere.com.
Contact:
Investors: 888-969-7879 IR@travere.com | Media: 888-969-7879 mediarelations@travere.com |
Last Trade: | US$16.38 |
Daily Change: | -0.53 -3.13 |
Daily Volume: | 950,181 |
Market Cap: | US$1.450B |
June 03, 2025 May 15, 2025 April 29, 2025 April 29, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load